Eris Lifesciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.1 pts more than Nifty Smallcap 250 and 9.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Eris Lifesciences reported strong FY2026 consolidated results with net profit after tax of Rs 647.51 crore, up 72.8% from Rs 374.67 crore in FY2025. Revenue from operations grew 8.15% to Rs 3,129.42 crore. The company declared an interim dividend of Rs 7.21 per share (721%) for FY2026-27. Operating margin expanded to 27.11% from 24.89% year-over-year. An exceptional item of Rs 17.24 crore was recorded due to new labour code implementation affecting gratuity and leave liabilities. A deferred tax credit of Rs 150 crore was recognized following the company's adoption of the new concessional tax regime. The company completed acquisition of remaining minority shares in Swiss Parenterals Limited and the branded probiotics business from Velbiom Probiotics for Rs 50 crore. Auditor changed from Deloitte Haskins & Sells LLP to Walker Chandiok & Co LLP for FY2026.
Strong profit growth and margin expansion are positive signals for shareholders. The clean audit opinion with no qualifications reinforces financial reliability. The significant dividend payout demonstrates management confidence in cash generation, though investors should note the auditor change and exceptional labour-related charge.